Premium
Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency Syndrome
Author(s) -
Zeind Caroline S.,
Cleveland Kerry O.,
Me Madhavi,
Brown James R.,
Solomon David K.
Publication year - 1996
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1996.tb03637.x
Subject(s) - flucytosine , medicine , cryptococcal meningitis , amphotericin b , fluconazole , meningitis , antifungal , cryptococcosis , intensive care medicine , cryptococcus , antiretroviral therapy , immunology , pediatrics , human immunodeficiency virus (hiv) , dermatology , viral disease , biology , microbiology and biotechnology , viral load
The optimum therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS) remains unresolved. Traditional therapy consists of amphotericin B with or without flucytosine. Obstacles exist in administering these agents to patients with AIDS. Mortality rates during initial therapy are relatively high. Given the lack of proved benefit, we do not recommend adding flucytosine to amphotericin B routinely. The search for more efficacious and less toxic agents continues. The oral triazoles, especially fluconazole, have increased the options for treatment of this disease. New strategies and novel approaches in managing cryptococcal meningitis in patients with AIDS continue to be developed.